Asia-Pacific Insulin Delivery Devices Market Share

Statistics for the 2023 & 2024 Asia-Pacific Insulin Delivery Devices market share, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Insulin Delivery Devices share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Asia-Pacific Insulin Delivery Devices Industry

The market is consolidated, with few players holding a significant market share in the current year. However, the insulin syringe market is highly fragmented, and many market players are based locally. Companies to expand their market presence are investing in R&D and collaborating with other major players to develop innovative solutions. Abbott and Novo Nordisk partnered to provide an integrated digital solution to people with diabetes using insulin. The collaboration may enable insulin data to be shared between Novo Nordisk's connected insulin pens and digital health tools compatible with the FreeStyle Libre portfolio of products.

Asia-Pacific Insulin Delivery Devices Market Leaders

  1. Novo Nordisk

  2. Medtronic

  3. Sanofi

  4. Eli Lilly and Company

  5. Ypsomed Holding

*Disclaimer: Major Players sorted in no particular order

Asia-Pacific Insulin Delivery Devices Market Concentration

Asia-Pacific Insulin Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)